SCHEMBL5403301

SCHEMBL5403301

O=C(O)CCN(Cc1cccnc1)C(=O)c1ccccc1-c1ccccc1C(=O)NCc1cc(F)ccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.49
KMT2A Q03164 3/20 0.48
HTT P42858 1/20 0.48
KDM4E B2RXH2 2/20 0.45
KCNA5 P22460 1/20 0.44
USP2 O75604 1/20 0.43
ALDH1A1 P00352 7/20 0.43
MAPK1 P28482 2/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.39
KCNK3 O14649 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5403400 0.92 KMT2A (0.47) PKMKMT2AHTTKDM4EKCNA5
SCHEMBL5411754 0.91 KMT2A (0.51) PKMKMT2AHTTKCNA5USP2
SCHEMBL5401085 0.91 KCNA5 (0.49) KMT2AHTTKCNA5ALDH1A1MAPK1
SCHEMBL5409425 0.89 PKM (0.59) PKMKMT2AHTTKDM4EKCNA5
SCHEMBL5392490 0.89 KMT2A (0.54) PKMKMT2AHTTKDM4EUSP2
SCHEMBL5394377 0.89 KCNA5 (0.46) KMT2AHTTKCNA5ALDH1A1LMNA
SCHEMBL5404066 0.88 KMT2A (0.53) PKMKMT2AHTTKDM4EUSP2
SCHEMBL5400960 0.87 HTT (0.57) PKMKMT2AHTTKDM4EUSP2
SCHEMBL5392891 0.86 KMT2A (0.51) PKMKMT2AHTTKCNA5USP2
SCHEMBL5394803 0.85 MAPK1 (0.51) KMT2AHTTKDM4EUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB PKM 880/4885KMT2A 2451/4885HTT 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.